Toggle Nav

DiscoveryProbe™ Tyrosine Kinase/Adaptors-related Compounds Panel

In stock
Catalog No.
L1018
 
Grouped product items
SizePriceStock Qty
5mg/well
$8,340.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

A wide range of well-characterized bioactive molecules that covers various targets related to tyrosine kinase/adaptors, including ALK, c-MET, VEGFR and Src etc. Facilitate your research towards the insights of cancer, immune response, growth and differentiation etc. Applicable in cellular assays, animal models and drug screenings etc.

Quality Control

Related Biological Data

TAE684 (NVP-TAE684)

Related Biological Data

TAE684 (NVP-TAE684)

Related Biological Data

Tivantinib(ARQ 197)

Related Biological Data

SGX-523

Related Biological Data

Regorafenib

Related Biological Data

Regorafenib
 

Advantages

Available in stock with overnight delivery and free shipping over $500 Cost-effective and competitive price to save your findings Potent, selective and cell-permeable in inhibiting or activating target molecules Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.) Detailed files describing potency, selectivity and applications etc. Supported by published data from top peer-reviewed journals Guaranteed high quality with NMR and HPLC validation

Featured Products of the Panel

Catalog No. Product Name Summary Targets CAS Number Smiles
A8328 LDK378 Potent ALK inhibitor Tyrosine Kinase/Adaptors|ALK 1032900-25-6 CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
B1402 GZD824 Bcr-Abl inhibitor,novel orally bioavailable Tyrosine Kinase/Adaptors|Bcr-Abl 1421783-64-3 CC1=CC=C(C(NC2=CC=C(CN3CCN(C)CC3)C(C(F)(F)F)=C2)=O)C=C1C#CC4=CN=C5C(C=NN5)=C4.CS(=O)(O)=O.CS(=O)(O)=O
A2838 OSI-930 Potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck Tyrosine Kinase/Adaptors|c-Kit 728033-96-3 C1=CC=C2C(=C1)C(=CC=N2)CNC3=C(SC=C3)C(=O)NC4=CC=C(C=C4)OC(F)(F)F
A1196 SGX-523 MET inibitor, highly selective, ATP-competitive Tyrosine Kinase/Adaptors|c-MET 1022150-57-7 CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2
A2977 Cabozantinib (XL184, BMS-907351) VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor Tyrosine Kinase/Adaptors|c-MET 849217-68-1 COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
A8320 PF-00562271 FAK/Pyk2 inhibitor,potent and ATP-competitive Tyrosine Kinase/Adaptors|FAK 939791-38-5 CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C.C1=CC=C(C=C1)S(=O)(=O)O
Download the Tyrosine Kinase/Adaptors-related Compounds Panel - XLSX       Download the Tyrosine Kinase/Adaptors-related Compounds Panel - SDF

References

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010 Jun 25;141(7):1117-34.
Abstract
Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands. It provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases. Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.
2. Wang Y, Wang L, Guan S et al.Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016 Jan 20;6:19423.
Abstract
ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. In this study, we show that a new ALK inhibitor AZD3463 effectively suppressed the proliferation of NB cell lines with wild type ALK (WT) as well as ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway and ultimately induced apoptosis and autophagy. In addition, AZD3463 not only enhanced the cytotoxic effects of doxorubicin on NB cells but also exhibited significant therapeutic efficacy on the growth of the NB tumors with WT and F1174L activating mutation ALK in orthotopic xenograft mouse models. These results indicate that AZD3463 is a promising therapeutic agent in the treatment of NB.